[adinserter block="3"]
News

Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin’s Lymphoma and Myeloma

HOUSTON & SEATTLE–(BUSINESS WIRE)–Indapta Therapeutics, Inc., a privately held biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and other immune-mediated diseases, today announced that the U.S. FDA has granted Fast Track […]

[adinserter block="3"]
[adinserter block="3"]